Customer Concentration

9 Months Ended

Sep. 30, 2019

Concentration Risk Disclosure [Text Block]

17. Concentration of Credit Risk

Product Line Concentration

The percentage of total revenue recognized, which individually accounted for 10% or more of the Company’s total revenues in one or more of the periods presented below, was as follows:



	Three Months Ended September 30,		Nine Months Ended September 30,
	2019	2018	2019⁽¹⁾	2018
LENSAR	18%	10%	19%	11%
Noden	27%	26%	36%	41%
Assertio	55%	72%	45%	43%

^{___________________}


⁽¹⁾	For the nine months ended September 30, 2019, the AcelRx royalty asset decrease in fair value of $57.7 million, is excluded from total revenue when calculating product line concentration.